Zhao Dan, Wu Ling-ying, Li Xiao-guang, Wang Xiao-bing, Li Mo, Li Yan-fen, Tian Hai-mei, Song Pei-pei, Liu Jing, Chang Qing-yun, Zhang Wei
Department of Gynecologic Oncology, Cancer Hospital & Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):855-8.
To explore the value of adenosine triphosphate-tumor chemosensitivity assay (ATP-TCA) in individualized treatment of recurrent epithelial ovarian cancer (REOC), and to evaluate the correlation between the in vitro chemosensitivity assay and clinical drug sensitivity.
Sixty-nine REOC specimens were tested by ATP-TCA assay retrospectively. The patients were divided into strong sensitive, moderate sensitively and resistant groups according to the ATP-TCA assay results. The clinical results were evaluated according to imaging and serum CA125 analysis. The correlation between in vitro ATP-TCA assay and clinical outcome was statistically analyzed by χ(2) test. The progression free survival (PFS) and overall survival (OS) of each group were analyzed using Kaplan-Meier method.
The results of ATP-TCA assay had significant correlation with clinical outcome. The clinical chemotherapy outcome became better with increased drug sensitivity in vitro (χ(2) = 9.066, P = 0.004). The sensitivity, specificity, positive predictive value, negative predictive value and accuracy rate for ATP-TCA method to predict the clinical chemotherapy sensitivity of REOC were 87.5%, 45.9%, 58.3%, 80.9% and 65.2%, respectively. The mean PFS of strong sensitive group, moderately sensitive group and resistant group were 187.1 days, 195.0 days and 60.3 days, respectively. The mean OS were 476.7, 335.7 and 237.5 days, respectively, following the start of TCA-directed therapy. The PFS and OS of the two sensitivity groups in vitro were significantly longer than that of the in vitro-resistant group (P < 0.01).
The results of ATP-TCA assay are well correlated with clinical treatment responses. The assay may be an important and useful method for individualized chemotherapy for recurrent ovarian cancer.
探讨三磷酸腺苷-肿瘤化疗药敏试验（ATP-TCA）在复发性上皮性卵巢癌（REOC）个体化治疗中的价值，并评估体外化疗药敏试验与临床药物敏感性之间的相关性。
回顾性分析69例REOC标本的ATP-TCA试验结果。根据ATP-TCA试验结果将患者分为强敏感组、中度敏感组和耐药组。根据影像学检查和血清CA125分析评估临床疗效。采用χ²检验对体外ATP-TCA试验与临床疗效之间的相关性进行统计学分析。采用Kaplan-Meier法分析各组的无进展生存期（PFS）和总生存期（OS）。
ATP-TCA试验结果与临床疗效显著相关。体外药物敏感性增加时，临床化疗效果改善（χ² = 9.066，P = 0.004）。ATP-TCA法预测REOC临床化疗敏感性的敏感性、特异性、阳性预测值、阴性预测值和准确率分别为87.5%、45.9%、58.3%、80.9%和65.2%。强敏感组、中度敏感组和耐药组的平均PFS分别为187.1天、195.0天和60.3天。TCA导向治疗开始后的平均OS分别为476.7天、335.7天和237.5天。体外两个敏感组的PFS和OS均显著长于体外耐药组（P < 0.01）。
ATP-TCA试验结果与临床治疗反应密切相关。该试验可能是复发性卵巢癌个体化化疗的一种重要且有用的方法。
